Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Alessandro, Paniccia, Ana L, Gleisner, Mazen S, Zenati, Amr I, Al Abbas, Jae Pil, Jung, Nathan, Bahary, Kenneth K W, Lee, David, Bartlett, Melissa E, Hogg, Herbert J, Zeh, Amer H, Zureikat
Publikováno v:
Annals of surgical oncology. 27(8)
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Matthew P. Holtzman, Melissa E. Hogg, J. Wallis Marsh, David L. Bartlett, James F. Pingpank, Mashaal Dhir, Amer H. Zureikat, David A. Geller, M. Haroon A. Choudry, Herbert J. Zeh, Heather L. Jones, Mazen S. Zenati, Nathan Bahary, Allan Tsung
Publikováno v:
Annals of Surgical Oncology. 25:550-557
In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver me
Autor:
Pranav Murthy, Amr I. Al Abbas, Mazen S. Zenati, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat, Brian A. Boone, Caroline J. Rieser, Herbert J. Zeh
Publikováno v:
Ann Surg Oncol
BACKGROUND. The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed a
Publikováno v:
Annals of surgical oncology. 25(7)
National adherence to treatment guidelines for pancreatic ductal adenocarcinoma (PDAC) is a concern. This study aims to evaluate national expected treatment (ET) adherence for all PDAC stages. We hypothesized that both patient and hospital demographi
Autor:
Nathan Bahary, Ahmad Hamad, Herbert J. Zeh, Mazen S. Zenati, Amer H. Zureikat, Mashaal Dhir, Aatur D. Singhi, Melissa E. Hogg
Publikováno v:
Annals of surgical oncology. 25(7)
Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA). This study aimed to compare neoadjuvant FOLFIRINOX and G-nP in the treatment of resectable (R) a
Autor:
Ahmad Hamad, Melissa E. Hogg, Caroline J. Rieser, Amr I. Al Abbas, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 25(12)
Serum carbohydrate antigen 19-9 (CA19-9) correlates with response to therapy and overall survival (OS) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to define the chronologic relationship between CA19-9 elevation and rad
Autor:
Nathan Bahary, Jennifer Steve, Herbert J. Zeh, David L. Bartlett, Amer H. Zureikat, Brian A. Boone, Melissa E. Hogg, Mazen S. Zenati, Aatur D. Singhi
Publikováno v:
Annals of Surgical Oncology. 21:4351-4358
Baseline carbohydrate antigen 19-9 (CA 19-9) is a useful prognostic marker in pancreatic ductal adenocarcinoma (PDA); however, data on the significance of a change in CA 19-9 following neoadjuvant therapy are lacking.All patients receiving neoadjuvan
Autor:
Kenneth K.W. Lee, David L. Bartlett, James F. Pingpank, Amer H. Zureikat, Haroon A. Choudry, Matthew P. Holtzman, Mazen S. Zenati, Lekshmi Ramalingam, Heather Jones, Herbert J. Zeh, Joshua Winer, Steven A. Ahrendt
Publikováno v:
Annals of Surgical Oncology. 21:1456-1462
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for peritoneal carcinomatosis (PC) of colorectal origin increases survival (OS) compared to systemic chemotherapy alone. Signet ring histology demonstrates aggressive